Table 3.
Clinical and tumour characteristics within the young-adult age group.
| Characteristic | 18–29 Years (n = 15) |
30–40 Years (n = 37) |
p-Value |
|---|---|---|---|
| Median Age at Diagnosis (Range) | 26 (18–29) | 38 (30–40) | |
| Gender | 0.07 | ||
| Male | 5 (33.3) | 23 (62.2) | |
| Female | 10 (66.6) | 14 (37.8) | |
| Median Baseline Tumour Size in mm (Range) | 45 (14–170) | 60 (6–370) | 0.23 |
| Primary Site Grouped | 0.48 | ||
| Gastric | 5 (33.3) | 19 (51.4) | |
| Small intestine | 9 (60.0) | 15 (40.5) | |
| Other | 1 (6.7) | 3 (8.1) | |
| Histology | 0.74 | ||
| Spindle cell | 12 (80.0) | 24 (73.5) | |
| Epithelioid | 0 (0.0) | 3 (8.8) | |
| Mixed type | 3 (20.0) | 6 (17.6) | |
| Unknown | 0 | 3 | |
| Tumour Status at Diagnosis | 1.00 | ||
| Local disease | 13 (87.7) | 32 (86.5) | |
| Metastasized | 2 (13.3) | 5 (13.5) | |
| Risk Category | 0.53 | ||
| Low/moderate | 7 (46.7) | 23 (62.2) | |
| High | 7 (53.3) | 14 (37.8) | |
| Unknown | 1 | 0 | |
| Mutation Status | 0.72 | ||
| KIT | 10 (66.7) | 24 (70.6) | |
| PDGFRA | 0 (0.0) | 3 (8.8) | |
| SDH deficient | 2 (13.3) | 2 (5.9) | |
| NF1 associated | 1 (6.7) | 1 (2.9) | |
| ETV6-NTRK3 gene fusion | 0 (0.0) | 1 (2.9) | |
| WT (min. KIT and PDGFRA) Unknown |
2 (13.3) 0 |
3 (8.8) 3 |
|
| Baseline Mitotic Rate | 0.32 | ||
| Low (≤ 5/5 mm2) | 8 (57.1) | 27 (73.0) | |
| High (> 5/5 mm2) Unknown |
6 (42.9) 1 |
10 (27.0) 0 |
|
| Surgery | 0.41 | ||
| Yes No |
14 (93.3) 1 (6.7) |
30 (81.1) 7 (18.9) |
|
| Patients who Received Surgery | 14 (93.3) | 30 (81.1) | 0.41 |
| Resection Margin | 0.26 | ||
| Negative (R0) | 12 (85.7) | 27 (96.4) | |
| Positive (R1/R2) | 2 (14.3) | 1 (3.6) | |
| Unknown | 0 | 2 | |
| Tumour Rupture | 1.00 | ||
| No | 11 (84.6) | 24 (80.0) | |
| Yes | 2 (15.4) | 5 (20.0) | |
| Unknown | 1 | 1 |
NF1 = neurofibromatosis type 1; WT = wildtype.